Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E1Z7 | ISIN: US86889P2083 | Ticker-Symbol:
NASDAQ
30.05.25 | 21:46
8,550 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SURROZEN INC Chart 1 Jahr
5-Tage-Chart
SURROZEN INC 5-Tage-Chart

Aktuelle News zur SURROZEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Surrozen secures patent for tissue repair technology1
SURROZEN Aktie jetzt für 0€ handeln
14.05.Surrozen, Inc.: Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway119Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating...
► Artikel lesen
09.05.Surrozen GAAP EPS of -$7.43 misses by $5.65, revenue of $0.98M1
09.05.Surrozen, Inc./DE - 10-Q, Quarterly Report1
09.05.Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update786SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively...
► Artikel lesen
09.05.Surrozen, Inc./DE - 8-K, Current Report1
31.03.Surrozen, Inc./DE - S-8, Securities to be offered to employees in employee benefit plans1
31.03.Surrozen, Inc.: Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates37SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
► Artikel lesen
31.03.Surrozen, Inc./DE - 10-K, Annual Report1
31.03.Surrozen, Inc./DE - 8-K, Current Report1
24.03.Surrozen, Inc./DE - 8-K, Current Report2
24.03.Surrozen shifts focus to eye disease treatments, secures $175M funding1
24.03.Surrozen, Inc.: Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases1
24.03.Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease-
06.11.24Surrozen, Inc.: Surrozen Provides Third Quarter 2024 Financial Results and Business Update373Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio...
► Artikel lesen
12.08.24Surrozen, Inc.: Surrozen Provides Second Quarter 2024 Financial Results and Business Update965Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application...
► Artikel lesen
10.06.24Surrozen, Inc.: Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan581SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1